NZ583803A - Agents with angiogenic and wound healing activity - Google Patents

Agents with angiogenic and wound healing activity

Info

Publication number
NZ583803A
NZ583803A NZ583803A NZ58380308A NZ583803A NZ 583803 A NZ583803 A NZ 583803A NZ 583803 A NZ583803 A NZ 583803A NZ 58380308 A NZ58380308 A NZ 58380308A NZ 583803 A NZ583803 A NZ 583803A
Authority
NZ
New Zealand
Prior art keywords
angiogenic
agents
wound healing
protein
healing activity
Prior art date
Application number
NZ583803A
Other languages
English (en)
Inventor
Keryn Johnson
Madhusudan Vasudevamurthy
Original Assignee
Ind Res Ltd
Australian Meat & Live Stock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007904857A external-priority patent/AU2007904857A0/en
Application filed by Ind Res Ltd, Australian Meat & Live Stock filed Critical Ind Res Ltd
Publication of NZ583803A publication Critical patent/NZ583803A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ583803A 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity NZ583803A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007904857A AU2007904857A0 (en) 2007-09-07 Agents with angiogenic and wound healing activity
PCT/AU2008/001319 WO2009029991A1 (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Publications (1)

Publication Number Publication Date
NZ583803A true NZ583803A (en) 2012-12-21

Family

ID=40428369

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583803A NZ583803A (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Country Status (6)

Country Link
US (1) US8404644B2 (enExample)
EP (2) EP2407175A1 (enExample)
JP (1) JP5685773B2 (enExample)
AU (1) AU2008295449A1 (enExample)
NZ (1) NZ583803A (enExample)
WO (1) WO2009029991A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2407175A1 (en) * 2007-09-07 2012-01-18 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
EP2512492A1 (en) 2009-12-14 2012-10-24 University of Massachusetts Methods of inhibiting cataracts and presbyopia
AU2012210013C1 (en) 2011-01-26 2017-06-01 Megmilk Snow Brand Co., Ltd. Sense-improving agent
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
JP2014005254A (ja) * 2012-06-26 2014-01-16 Bfsr:Kk 熱傷由来全身性炎症反応症候群の予防外用薬
MX366115B (es) 2013-03-14 2019-06-27 Univ Massachusetts Metodos para inhibir cataratas y presbicia.
KR20170040648A (ko) * 2015-10-05 2017-04-13 차의과학대학교 산학협력단 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물
CR20180294A (es) 2015-11-13 2018-08-10 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia
US20220088265A1 (en) * 2019-02-08 2022-03-24 Manmeet Kaur Biomaterials and methods related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187482A1 (en) * 1995-10-13 1997-04-14 Eri Inoue Pharmaceutical composition
WO1999051738A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-4
WO1999051634A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-3
AU6290299A (en) 1998-10-15 2000-05-01 E.I. Du Pont De Nemours And Company Polymers, containing a fluorocyclobutyl ring and their preparation
WO2004005883A2 (en) 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
JP3783200B2 (ja) * 2000-08-24 2006-06-07 株式会社加美乃素本舗 血管新生剤
US7263214B2 (en) 2002-05-15 2007-08-28 Ge Medical Systems Global Technology Company Llc Computer aided diagnosis from multiple energy images
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
WO2004096277A1 (ja) * 2003-05-01 2004-11-11 Kyoto University 眼内血管新生疾患の予防又は治療剤
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
AU2005275062A1 (en) * 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
KR101840445B1 (ko) 2005-02-03 2018-05-04 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
WO2006091930A2 (en) 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
WO2007084895A2 (en) 2006-01-13 2007-07-26 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
US20100004168A1 (en) * 2006-06-30 2010-01-07 The Johns Hopkins University Use of Crystallin For The Modulation of Angiogenesis
KR20100027091A (ko) 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
CA2671724A1 (en) 2006-12-11 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Alpha b-crystallin as a therapy for inflammation
WO2009012224A2 (en) 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
EP2407175A1 (en) * 2007-09-07 2012-01-18 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity

Also Published As

Publication number Publication date
WO2009029991A1 (en) 2009-03-12
AU2008295449A1 (en) 2009-03-12
EP2190455A1 (en) 2010-06-02
JP2010538020A (ja) 2010-12-09
JP5685773B2 (ja) 2015-03-18
EP2407175A9 (en) 2012-02-29
US8404644B2 (en) 2013-03-26
US20100210531A1 (en) 2010-08-19
EP2190455A4 (en) 2010-11-24
EP2407175A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
NZ583803A (en) Agents with angiogenic and wound healing activity
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
MX369385B (es) Productos para cicatrizar heridas tisulares.
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
BR112013028914A2 (pt) antagonistas de receptores de integrina e seus métodos de uso
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
NZ707377A (en) Combination therapy methods for treating proliferative diseases
BR112013003677A2 (pt) uso de agente farmacologicamente ativo e forma de dosagem farmacêutica
NZ606825A (en) Methods and compositions for treating complement-associated disorders
ZA201104600B (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
WO2009156735A3 (en) New therapeutic agents
NZ603319A (en) Diabetes therapy
IL201479A (en) Use of tapentadol for the preparation of pain medication
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2009011900A (es) Curacion de herida diabetica.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
IL205290A (en) A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2008011321A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
WO2022019839A8 (en) Crystalline zirconium phosphate for use in therapy, pharmaceutical composition, and use of the same
TN2010000249A1 (en) New medical use of 3-(2,2,2-trimethylhydrazinium ) propionate salts

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 SEP 2015 BY AJ PARK

Effective date: 20130604

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 943419, MEAT + LIVESTOCK AUSTRALIA LIMITED, LEVEL 1, 165 WALKER STREET, NORTH SYDNEY, NSW 2060, AU; 3037568, INDUSTRIAL RESEARCH LIMITED, GRACEFIELD RESEARCH CENTRE, 69 GRACEFIELD ROAD, LOWER HUTT, NZ

Effective date: 20140114

LAPS Patent lapsed